Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Teik C Ooi

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Obstetric Medicine|August 12, 2016
Severe gestational hypertriglyceridemia: A practical approach for cliniciansBertha Wong, Teik C Ooi, Erin Keely
Journal of Clinical Lipidology|October 9, 2020
Relative effect of hypertriglyceridemia on non-HDLC and apolipoprotein B as cardiovascular disease risk markersCathy J Sun, Diane Brisson, Daniel Gaudet, et al.
Canadian Journal of Diabetes|June 19, 2022
A More Atherogenic Lipoprotein Status Is Present in Adults With Type 2 Diabetes Mellitus Than in Those Without With Equivalent Degrees of HypertriglyceridemiaCathy J Sun, Diane Brisson, Rahul Sharma, et al.
The Canadian Journal of Cardiology|December 31, 2022
Comparison of Three Methods for LDLC Calculation for Cardiovascular Disease Risk Categorisation in Three Distinct Patient PopulationsCathy J Sun, Christopher McCudden, Diane Brisson, et al.
Journal of the Endocrine Society|February 4, 2020
Calculated Non-HDL Cholesterol Includes Cholesterol in Larger Triglyceride-Rich Lipoproteins in HypertriglyceridemiaCathy J Sun, Christopher McCudden, Diane Brisson, et al.
Obesity (Silver Spring, Md.)|September 25, 2016
The anti-adipogenic effect of peripheral blood mononuclear cells is absent with PCSK9 loss-of-function variantsAnneMarie Gagnon, Teik C Ooi, Marion Cousins, et al.
Metabolism: Clinical and Experimental|September 16, 2015
The contribution of PCSK9 levels to the phenotypic severity of familial hypercholesterolemia is independent of LDL receptor genotypeJean-Philippe Drouin-Chartier, André J Tremblay, Jean-Charles Hogue, et al.
Systematic Reviews|June 2, 2012
Interactions of commonly used dietary supplements with cardiovascular drugs: a systematic reviewSalmaan Kanji, Dugald Seely, Fatemeh Yazdi, et al.
Current Vascular Pharmacology|July 17, 2019
Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Narrative ReviewGenovefa D Kolovou, Gerald F Watts, Dimitri P Mikhailidis, et al.
Current Vascular Pharmacology|May 8, 2019
Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Main TextGenovefa D Kolovou, Gerald F Watts, Dimitri P Mikhailidis, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Obstetric Medicine|August 12, 2016
Severe gestational hypertriglyceridemia: A practical approach for cliniciansBertha Wong, Teik C Ooi, Erin Keely
Journal of Clinical Lipidology|October 9, 2020
Relative effect of hypertriglyceridemia on non-HDLC and apolipoprotein B as cardiovascular disease risk markersCathy J Sun, Diane Brisson, Daniel Gaudet, et al.
Canadian Journal of Diabetes|June 19, 2022
A More Atherogenic Lipoprotein Status Is Present in Adults With Type 2 Diabetes Mellitus Than in Those Without With Equivalent Degrees of HypertriglyceridemiaCathy J Sun, Diane Brisson, Rahul Sharma, et al.
The Canadian Journal of Cardiology|December 31, 2022
Comparison of Three Methods for LDLC Calculation for Cardiovascular Disease Risk Categorisation in Three Distinct Patient PopulationsCathy J Sun, Christopher McCudden, Diane Brisson, et al.
Journal of the Endocrine Society|February 4, 2020
Calculated Non-HDL Cholesterol Includes Cholesterol in Larger Triglyceride-Rich Lipoproteins in HypertriglyceridemiaCathy J Sun, Christopher McCudden, Diane Brisson, et al.
Obesity (Silver Spring, Md.)|September 25, 2016
The anti-adipogenic effect of peripheral blood mononuclear cells is absent with PCSK9 loss-of-function variantsAnneMarie Gagnon, Teik C Ooi, Marion Cousins, et al.
Metabolism: Clinical and Experimental|September 16, 2015
The contribution of PCSK9 levels to the phenotypic severity of familial hypercholesterolemia is independent of LDL receptor genotypeJean-Philippe Drouin-Chartier, André J Tremblay, Jean-Charles Hogue, et al.
Systematic Reviews|June 2, 2012
Interactions of commonly used dietary supplements with cardiovascular drugs: a systematic reviewSalmaan Kanji, Dugald Seely, Fatemeh Yazdi, et al.
Current Vascular Pharmacology|July 17, 2019
Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Narrative ReviewGenovefa D Kolovou, Gerald F Watts, Dimitri P Mikhailidis, et al.
Current Vascular Pharmacology|May 8, 2019
Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Main TextGenovefa D Kolovou, Gerald F Watts, Dimitri P Mikhailidis, et al.
Pageof 2